Your Cart is Empty
BUY 1 GET 1 FREE · AUTO APPLIES AT CHECKOUT
Medical Disclaimer | This article is for informational and educational purposes only. Psoriasis is a chronic autoimmune condition requiring dermatologist management. CBD is not a treatment for psoriasis and is not a substitute for evidence-based medical therapies. PureCraft CBD products are broad-spectrum zero-THC, batch-verified at purecraftcbd.com/pages/faq. Individual results may vary.
Psoriasis is a chronic immune-mediated skin condition affecting approximately 2–3% of the global population — around 125 million people worldwide. It is classified as an autoimmune condition because its pathology is driven by dysregulated T-cell activity: Th1 and Th17 cells produce elevated IL-17, IL-22, and TNF-α that act on keratinocytes (skin cells) to drive hyperproliferation. Normal keratinocytes complete their maturation cycle in 28–30 days; in psoriatic skin, this cycle is compressed to 3–5 days, producing the characteristic thick, silvery plaques of accumulated immature keratinocytes.
The result is the hallmark psoriatic plaque: raised, well-demarcated, erythematous (red) skin covered with silvery-white scale, typically occurring on the scalp, elbows, knees, lower back, and nails. Plaque psoriasis is the most common form (85–90% of cases); other types include guttate, inverse, pustular, and erythrodermic psoriasis. The condition follows a relapsing-remitting pattern — flares triggered by stress, infections, medications, skin trauma (Koebner phenomenon), and weather changes; remissions of variable duration.
Psoriasis is not purely a skin condition — it is associated with significant systemic comorbidities including psoriatic arthritis (30% of patients), cardiovascular disease, metabolic syndrome, and depression. The skin and joint manifestations share the same fundamental immune-mediated mechanism, which is why the most effective psoriasis treatments (biologics targeting IL-17, IL-23, and TNF-α) work systemically — and why CBD's CB2 immunomodulatory and skin-specific ECS mechanisms are relevant to multiple aspects of psoriatic disease. SeeCBD and Autoimmune Conditions: What We Know So Farfor the complete autoimmune condition context.
The skin is one of the richest ECS-expressing tissues in the body — keratinocytes, melanocytes, sebocytes, hair follicle cells, Langerhans cells, mast cells, and sensory nerve terminals all express CB1, CB2, TRPV1, and TRPA1 receptors, as well as produce endocannabinoids and FAAH enzyme locally. This 'cutaneous ECS' regulates fundamental skin biology: keratinocyte proliferation and differentiation, sebum production, hair growth, inflammatory signaling, and nociception.
In the psoriasis context, CB1 and CB2 receptor activation in keratinocytes produces anantiproliferative effect — slowing the abnormally accelerated keratinocyte turnover that produces psoriatic plaques. Oláh et al. (2014) demonstrated this in sebocytes (closely related sebaceous gland cells); the antiproliferative ECS signaling in keratinocytes is consistent with the broader cutaneous ECS biology. CBD's modulation of the cutaneous ECS — through FAAH inhibition (elevating anandamide) and direct CB2 activation — potentially applies this antiproliferative signal to psoriatic keratinocytes.
Pruritus (itch) is one of the most distressing psoriasis symptoms — affecting up to 90% of psoriasis patients and significantly impacting sleep, work, and quality of life. Psoriatic itch involves multiple mechanisms, including TRPV1 sensitization in cutaneous nerve endings by the inflammatory cytokine environment (IL-31 is the primary 'itch cytokine' in psoriasis, acting partly through TRPV1 pathways).
CBD Topical applied to psoriatic plaques delivers TRPV1 desensitization effects to the sensitized cutaneous nerve endings in and around the plaque — reducing the pruritic signal from these chronically sensitized TRPV1-positive nerve fibers. This anti-pruritic mechanism is separate from the antiproliferative CB1/CB2 mechanism — it addresses the itch symptom rather than the plaque formation, providing an additional rationale for topical CBD in psoriasis management beyond the proliferation-targeting effect.
The IL-17, IL-22, and TNF-α cytokines that drive psoriatic keratinocyte hyperproliferation are products of the Th17 T-cell activation that underlies psoriatic autoimmunity. CBD's CB2 activation shifts macrophage and T-cell phenotype toward anti-inflammatory states — reducing the pro-inflammatory cytokine production that sustains psoriatic plaque formation. This CB2 immunomodulatory effect is well-documented in the general inflammatory context; its specific relevance to psoriatic Th17 cytokine reduction is mechanistically plausible but not directly confirmed in human psoriasis trials.
SystemicCBD Oil provides this CB2 immunomodulatory effect beyond the skin surface — potentially addressing the systemic T-cell dysregulation that drives psoriasis rather than only the local skin manifestation. For patients with psoriatic arthritis (where the same T-cell dysregulation produces joint inflammation), systemicCBD Oil is particularly relevant: it addresses both the cutaneous and articular inflammatory burden through the same CB2 mechanism. SeeCBD for Arthritis: The Complete Evidence-Based Guide for the joint inflammation framework.
The most frequently cited CBD-skin research is Oláh et al. (2014), published inThe Journal of Clinical Investigation. This study examined CBD's effects on human sebocytes — sebaceous gland cells that share regulatory biology with keratinocytes. The key findings: CBD inhibited lipid synthesis, normalized sebocyte differentiation, and suppressed pro-inflammatory cytokine production via TRPV4 receptor activation. The study concluded that CBD may offer novel treatment approaches for seborrhoeic dermatitis and acne.
For psoriasis specifically, the relevance is indirect but mechanistically connected: sebocytes and keratinocytes share ECS-mediated antiproliferative signaling, and the CBD-driven normalization of abnormal cell proliferation seen in sebocytes is consistent with the antiproliferative ECS biology in keratinocytes. The Oláh study does not directly confirm CBD's antiproliferative effect in psoriatic keratinocytes — that direct human trial does not yet exist — but provides the most proximate skin-cell evidence for CBD's cutaneous ECS effects.
Palmieri et al. (2019) published an observational study inClinical Therapeutics examining a CBD-enriched ointment applied twice daily for 3 months in 20 patients with skin conditions including psoriasis and eczema. Findings: significant improvement in Psoriasis Area and Severity Index (PASI) scores, skin hydration parameters, and transepidermal water loss (TEWL — a marker of skin barrier function) in the psoriasis patients. Patient-reported symptoms (itch, burning) also improved.
Important caveats: this was an observational study without a placebo control group — improvement could reflect regression to the mean, seasonal variation in psoriasis activity, or placebo effects. The study size was small (20 patients across multiple skin conditions). It is not a randomized controlled trial. These limitations mean the Palmieri findings are hypothesis-generating rather than confirmatory — they suggest a signal worth investigating in controlled trials rather than establishing CBD as an evidence-based psoriasis treatment.
The honest state of CBD-psoriasis evidence in 2027: the biological rationale is sound (cutaneous ECS antiproliferative signaling, TRPV1 anti-pruritic mechanism, CB2 immunomodulation), the observational clinical data is promising (Palmieri 2019 showed PASI improvement), but randomized controlled trial confirmation does not exist. CBD is not an FDA-approved or dermatologist-endorsed first-line psoriasis treatment. It is a biologically plausible, low-risk topical supplement that may complement evidence-based psoriasis management — not replace it.
Frequency: ApplyCBD Topicals twice daily — morning and before sleep. Twice-daily application maintains continuous CB2 and TRPV1 activity at the psoriatic plaque throughout the day and overnight healing window
Application technique: ApplyCBD Topicals to clean, dry skin. For active plaques, apply directly to the plaque surface and extend slightly into the perilesional skin (the surrounding normal skin that is often the leading edge of plaque expansion). Gently massage in a circular motion for 30–60 seconds to assist dermal absorption. Do not apply to open, cracked, or bleeding skin
Plaque thickness consideration:Thick psoriatic plaques (particularly on elbows and knees) reduce dermal absorption by creating a physical barrier of scale. Gentle physical removal of scale (through occlusive moisturizer plus gentle wiping — not aggressive scrubbing) before applyingCBD Topicals improves penetration. Some dermatologists recommend keratolytic agents (salicylic acid) for scale removal —CBD Topicals can be applied after the keratolytic has been absorbed or rinsed
Body area considerations:Scalp psoriasis requires a different formulation approach than body plaques — standard topical CBD formulations are designed for body skin. For scalp psoriasis specifically, consult a dermatologist for appropriate scalp-specific formulation options. Face psoriasis requires careful application with avoidance of eye contact
Duration before assessment:Psoriasis plaques respond slowly — assessCBD Topicals benefit over a minimum of 4–6 weeks of consistent twice-daily application. Short-term (1–2 week) assessment underestimates the cumulative ECS benefit that requires consistent receptor engagement to produce meaningful tissue-level change
CBD Oil 15–20mg daily provides systemic CB2 immunomodulatory effects that complement the localizedCBD Topicals application. The rationale: psoriasis is a systemic immune condition, and the cutaneous manifestation is an expression of systemic T-cell dysregulation. Addressing only the skin with topical CBD while the underlying systemic T-cell activation continues is mechanistically incomplete. SystemicCBD Oil contributes the CB2-mediated macrophage and T-cell phenotype modulation that may reduce the systemic inflammatory burden driving both the skin plaques and (in patients with psoriatic arthritis) the joint inflammation.
For psoriatic arthritis specifically:CBD Oil 20mg daily provides the CB2 and TRPV1 systemic anti-inflammatory coverage most relevant to the joint manifestation, whileCBD Topicals addresses the cutaneous plaque locally. This two-product approach is the most comprehensive CBD protocol for psoriasis patients with joint involvement. SeeCBD for Arthritis: The Complete Evidence-Based Guide.
Psoriatic arthritis (PsA) affects approximately 30% of people with psoriasis — producing an inflammatory oligoarthritis or polyarthritis that shares the same underlying Th17 cytokine pathology as the skin disease. The joints, tendons (enthesitis), and sometimes the spine (axial PsA) are affected. PsA is distinct from rheumatoid arthritis in its asymmetric distribution, DIP joint involvement, and association with nail psoriasis and the cutaneous disease.
For PsA patients, the CBD protocol addresses both dimensions:CBD Oil 20mg daily for systemic CB2 anti-inflammatory joint and skin management,CBD Topicals to affected joints (fingers, wrists, ankles, knees) for localized CB2 and TRPV1 management, andCBD Topicals to skin plaques as a separate application.CBD+CBN Sleep Gummies nightly address the sleep disruption that PsA's joint pain commonly produces. The combination provides CBD coverage of the skin disease, joint disease, and sleep impairment that characterize the full PsA burden — a more comprehensive approach than addressing only the skin or only the joints.
|
Treatment |
Mechanism |
CBD Alongside? |
Notes |
|
Topical corticosteroids (mild–moderate) |
Anti-inflammatory; reduces keratinocyte proliferation |
Yes — CBD Topical can complement; apply at different times |
Do not mix CBD Topical with corticosteroid cream in same application |
|
Topical vitamin D analogues (calcipotriene) |
Reduces keratinocyte proliferation; differentiation promotion |
Yes — CBD Topical compatible; separate application timing |
CBD's antiproliferative mechanism is complementary to vitamin D analogue action |
|
Biologic drugs (IL-17, IL-23, TNF inhibitors) |
Systemic immune modulation — target specific cytokines |
Discuss with dermatologist — CBD + biologic: limited interaction data |
Mandatory dermatologist discussion; biologics are high-value psoriasis treatments; CBD is a low-risk complement |
|
Phototherapy (UVB, PUVA) |
Reduces keratinocyte turnover; immunomodulation |
Yes — CBD Topical between sessions |
No significant interaction expected; topical CBD between sessions is reasonable |
|
Methotrexate |
Systemic antiproliferative immunosuppressant |
CAUTION — both are hepatically metabolized; liver monitoring required |
Mandatory physician discussion; CBD may increase methotrexate levels via CYP450; liver function monitoring required |
|
Cyclosporine |
Systemic immunosuppressant |
CAUTION — CYP3A4 substrate; CBD may increase cyclosporine levels |
Mandatory physician discussion — narrow therapeutic index; serious interaction risk |
The treatment table highlights the two most important interaction cautions:methotrexate and cyclosporine both have CYP450 interactions with CBD that can increase drug levels — both require mandatory physician discussion before startingCBD Oil. These are systemic medications with narrow therapeutic windows; CBD's CYP450 inhibition is not a minor consideration in this context. For the complete drug interaction framework, seeCBD and Drug Interactions: The Complete CYP450 Guide.
For psoriasis patients on biologic drugs (the most effective systemic treatments available — secukinumab, ixekizumab, guselkumab, adalimumab): the interaction data is limited, but biologics work through highly specific antibody-target mechanisms rather than CYP450 pathways, reducing the likelihood of pharmacokinetic interaction with CBD. Dermatologist discussion is appropriate but the interaction risk is lower than with methotrexate or cyclosporine.
CBD has a biologically plausible case for psoriasis benefit through three mechanisms: CB1/CB2 antiproliferative signaling in keratinocytes (potentially slowing the accelerated turnover that produces plaques), TRPV1 anti-pruritic desensitization (reducing itch), and CB2 immunomodulatory effects on the Th17-driven cytokine environment. Palmieri et al. (2019) showed PASI score improvement with CBD ointment in a small observational study. This is promising but not confirmed in randomized controlled trials. CBD is not an evidence-based first-line psoriasis treatment — it is a biologically plausible, low-risk complement to dermatologist-directed management.
CBD Topicals applied twice daily to psoriatic plaques engages CB1/CB2 antiproliferative signaling and TRPV1 anti-pruritic mechanisms in the psoriatic epidermis. The Palmieri et al. (2019) observational data showed PASI improvement with CBD ointment over 3 months. Plaque reduction from CBD topical is a slow process — assess over 4–6 weeks minimum of consistent application. Thick plaques may require keratolytic pre-treatment to improve CBD penetration through the scale barrier. CBD Topical is not a substitute for topical corticosteroids or vitamin D analogues for moderate-to-severe plaques.
ApplyCBD Topicals to clean, dry skin twice daily — morning and before sleep. Apply directly to the plaque surface and extend slightly into surrounding perilesional skin. Gently massage for 30–60 seconds. For thick scaly plaques on elbows or knees, consider gentle scale removal before application to improve absorption. Do not apply to cracked, bleeding, or infected skin. Assess benefit over a minimum 4–6 weeks — psoriasis plaques respond slowly to any topical intervention. For scalp psoriasis, body-formulation CBD Topical is not appropriate; consult a dermatologist.
Yes — this is the most mechanistically direct CBD application for psoriasis. Psoriatic pruritus involves TRPV1 sensitization in cutaneous nerve endings by the IL-31 and inflammatory cytokine environment.CBD Topicals delivers TRPV1 desensitization effects to these sensitized nerve fibers — reducing the itch signal intensity. Many psoriasis patients report that itch reduction is the most immediately noticeable effect of CBD Topical application, occurring within the first week of use, before plaque morphology visibly changes. This faster onset for itch vs. plaque improvement reflects the different timescales of neurological TRPV1 desensitization vs. keratinocyte proliferation cycle changes.
No — topical corticosteroids have a much stronger evidence base for psoriasis plaque reduction than CBD Topical. Corticosteroids are the cornerstone of topical psoriasis management, with decades of RCT evidence and clear PASI improvement data across severity levels.CBD Topicals is a potential complement to corticosteroids rather than a replacement. UsingCBD Topicals alongside topical corticosteroids — applied at different times, not mixed — may extend the anti-inflammatory and antiproliferative activity between corticosteroid applications, potentially reducing the frequency of corticosteroid use needed for maintenance. The corticosteroid-sparing potential of CBD Topical in psoriasis has not been tested in controlled trials but is mechanistically plausible.
Yes — psoriatic arthritis shares the same Th17 CB2-relevant cytokine mechanism as skin psoriasis.CBD Oil20mg daily provides systemic CB2 immunomodulatory and anti-inflammatory effects relevant to the joint inflammation, whileCBD Topicals to affected joints addresses the localized periarticular inflammatory burden. The combination — systemic oil for both skin and joint CB2 modulation, topical for local joint CB2 and TRPV1 management, Sleep Gummies for pain-disrupted sleep — is the most comprehensive CBD protocol for the psoriatic arthritis presentation. SeeCBD for Arthritis: The Complete Evidence-Based Guide for the complete arthritis framework.
Twice daily — morning and before sleep — is the appropriate frequency forCBD Topicals in psoriasis management. Twice-daily application maintains continuous CB2 and TRPV1 receptor engagement at the plaque throughout the day and overnight. Single daily application may be insufficient for continuous receptor occupancy given typical topical product absorption timescales. More frequent application (3–4x daily) may be appropriate during active flares with significant itch, but twice daily is the sustainable long-term maintenance frequency.
SystemicCBD Oil affects the immune system through CB2 receptor modulation — shifting macrophage and T-cell phenotype from pro-inflammatory (Th17-promoting) toward anti-inflammatory (Th2-promoting) states. This immune phenotype shift is relevant to psoriasis because the Th17 over-activation is the fundamental immunological driver of the condition. Whether CBD's CB2-mediated immune modulation is sufficient to produce meaningful clinical benefit in psoriasis at supplement doses — without the targeted potency of biologic drugs — is not established in human trials. SeeCBD and Autoimmune Conditions: What We Know So Far for the complete autoimmune immune modulation context.
Psoriasis presents a strong biological rationale for CBD through three converging mechanisms: cutaneous ECS antiproliferative signaling in keratinocytes, TRPV1 anti-pruritic desensitization for itch management, and CB2 immunomodulatory effects on the T-cell cytokine environment that drives psoriatic inflammation. The observational clinical evidence (Palmieri 2019) is promising without being definitive. The honest positioning: CBD is a biologically plausible, low-risk topical and systemic complement to dermatologist-directed psoriasis management — not a standalone treatment or a replacement for evidence-based therapies.
The psoriasis CBD protocol:CBD Topicals — twice daily to plaques and perilesional skin; separate application to affected joints if psoriatic arthritis is present.PureCraft CBD Oil 1000mg — 15–20mg AM daily for systemic CB2 immunomodulatory support.CBD+CBN Sleep Gummiesnightly if psoriatic itch or joint pain disrupts sleep. Zero THC, nano-optimized,batch-tested COA.browse all PureCraft CBD products.
Medical Disclaimer| Psoriasis requires dermatologist diagnosis and management. CBD is not a treatment for psoriasis. If you take methotrexate or cyclosporine, discuss CBD with your prescriber before starting — CYP450 interactions are clinically significant with these medications. PureCraft CBD products are not intended to diagnose, treat, cure, or prevent any disease. Individual results may vary.
•CBD for Eczema and Skin Inflammation: What Works?
•CBD Cream for Pain: Does It Really Work?
•CBD for Inflammation: What the Science Actually Says
•CBD for Arthritis: The Complete Evidence-Based Guide
•CBD and Autoimmune Conditions: What We Know So Far
•CBD for Lupus: Inflammation, Fatigue, and Autoimmune Symptom Management
•CBD and Drug Interactions: The Complete CYP450 Guide
•CBD for Anxiety: The Complete 2026 Guide
•CBD for Sleep: The Ultimate 2026 Guide to Better Rest
•What Is the Endocannabinoid System? A Complete Guide
Medical Disclaimer | Sauna use is contraindicated in certain cardiovascular conditions, pregnancy, and with medications that impair heat tolerance...
Read More
Medical Disclaimer | Cold water immersion is contraindicated in people with cardiovascular conditions, Raynaud's disease, hypertension, or cold ur...
Read More
Medical Disclaimer | This article is for informational and educational purposes only. Intermittent fasting and CBD supplementation should be appro...
Read More